Skip to main content
Fig. 5 | BMC Cancer

Fig. 5

From: Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion

Fig. 5

Dual mTORC1/2 inhibitor and selective mTORC1 inhibitor treatments achieve on-target effects in TfRCC xenograft models. Western Blot of UOK120 and UOK146 xenograft tumors 6 h after treatment with a selective mTORC1 inhibitor (sirolimus), a dual mTORC1/2 inhibitor (AZD8055) or respective vehicle controls. Reduction in phosphorylation levels of S6 with sirolimus compared to vehicle control (IPC) confirmed on-target inhibition of mTORC1. Reduction in phosphorylation levels of S6(Ser240/244) and Akt (Thr473) by AZD8055 treatment compared to vehicle control (POC) confirmed on-target inhibition of mTORC1 and mTORC2, respectively. Levels of phosphorylated mTOR were suppressed with AZD8055 but not sirolimus compared to respective controls

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us